Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control
about
Residual macrovascular risk in 2013: what have we learned?The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia.The role of triglycerides in atherosclerosis.Lipid-related residual risk and renal function for occurrence and prognosis among patients with first-event acute coronary syndrome and normal LDL cholesterolCorrelation between biochemical indicators of blood lipid with cerebral vascular diseasesLow incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.Effects of Family Meal Frequency on Risk Factors for Cardiovascular Disease in Korean Elderly Males and Females.Effect of DanQi Pill on PPARα, lipid disorders and arachidonic acid pathway in rat model of coronary heart disease.Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.Reducing vascular events risk in patients with dyslipidaemia: an update for cliniciansResidual Dyslipidemia Leads to Unfavorable Outcomes in Patients with Acute Coronary Syndrome after Percutaneous Coronary InterventionA Novel Medical Treatment for Lipid Control in Patients with Unstable Angina Pectoris and Statin-Induced Liver Dysfunction.Beneficial effects of the RESMENA dietary pattern on oxidative stress in patients suffering from metabolic syndrome with hyperglycemia are associated to dietary TAC and fruit consumption.Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Optimal cutoff of the triglyceride to high-density lipoprotein cholesterol ratio to detect cardiovascular risk factors among Han adults in Xinjiang.Nutrients utilization in obese individuals with and without hypertriglyceridemia.Apolipoprotein A5 gene variants and the risk of coronary heart disease: a case‑control study and meta‑analysis.The role of atherosclerosis imaging in redefining normal and abnormal cholesterol values, and risk reduction in primary prevention statin trials.The epidemiological concept of residual risk.Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.Dyslipidemias in the prevention of cardiovascular disease: risks and causality.Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement.Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonistsEarly investigational drugs targeting PPAR-α for the treatment of metabolic disease.Targeting ApoC-III to Reduce Coronary Disease Risk.Hypertriglyceridaemia and risk of coronary artery disease.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea.Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study.Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study.Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome.Relationship Between Alcohol Consumption and Serum Lipid Profiles Among Middle-Aged Population in China: A Multiple-Center Cardiovascular Epidemiological Study.Triglyceride-to-HDL cholesterol ratio. Predictive value for CHD severity and new-onset heart failure.Coronary artery calcium: utilization for primary prevention of CHD.Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population.Visceral adiposity index and triglyceride/high-density lipoprotein cholesterol ratio in hypogonadism.
P2860
Q26996039-A27D6EAF-A68A-485A-9E64-8DD675C8023DQ30356827-FC2E8E30-6ED7-4622-A9D8-1BA07C83EFBDQ33972551-9D48644D-DB61-487E-AC5F-ACBA468D6FE0Q35110779-A32D72B0-0207-456F-B374-D555169D1BD8Q35602424-9A3A3628-E247-4182-AD2A-2DCB40337B56Q35607759-E9BEA577-EF49-42A6-96BA-24A904928517Q35632270-352AF322-A287-4B78-AE32-3E08578A68B3Q35650429-F6033B1F-6360-44B6-823D-B082665EBE4DQ35668248-D2BF561B-6E17-47D6-947E-65E319F3EBFFQ35965141-1EC1468A-AB8C-4B5A-92A4-7BF09C3271AAQ36368459-56152601-8CAA-45B3-9912-3ABA62FF9B37Q36443768-40FBCFF5-25FE-43B0-8E20-1A5D18E15191Q36530790-9AFF9447-3012-48B0-A47D-20A71E76CDF5Q36721590-CBFFC586-E6F7-42AC-A680-2A1808366F78Q36820389-7D683C00-0A3B-47DB-9E0E-5E3A4086334EQ37119482-C098FA77-69B3-4790-B3F6-8B1145AA4CB4Q37254899-7F78331A-D68A-4D11-91EC-7761C7AEB78EQ37261410-8749869E-D0A2-4454-A0C9-BA0C7FE85063Q37617746-6796C7E5-8A0E-4A70-A4B5-7C86D5174415Q37693916-E051DF87-DF2D-4D86-A2FD-D431289AEF0AQ37906376-3E95183B-9CA7-4E75-AB2D-20308348DF01Q37947160-C1E453A8-4F06-49B6-9E5D-B18FB38E9E38Q38014975-E014292A-FEDC-4F02-977C-515500368E5CQ38042396-49FCE4A3-0789-4E1E-A436-BD7B12A0A875Q38079763-7635D191-EE6B-4F41-A277-CB5113905E7CQ38086841-8F616F43-B0AD-4DA2-A055-B46D87199177Q38110581-A41259C8-3644-4E13-A448-E7E98AA91F68Q38325814-E361CACC-2FE2-45F7-9706-3B41DA9CFD4AQ38904497-363FAE1B-6D90-4B36-8ED9-114A9A446AD6Q39181612-82063C43-DF14-43E2-AFA1-5E75B4549575Q39200940-FDF8F382-E0D6-4C82-B5C1-398EE1F29675Q39593365-729D13AF-560A-4914-BBD3-C22C3EE4E543Q40364483-F29B755A-9C69-4B6F-9472-28D454F1323DQ40521235-24179595-AFD1-4CFC-A0F1-78A8434859DCQ40666385-10EFD383-3909-4FB4-BBD6-A48DEF6D9F42Q44319945-C9004E32-DD52-4543-9B7B-24C45F808A4AQ44439789-37FA447E-3048-4905-9A07-B6811D893D6EQ45891673-EA8A63CA-B9B3-44CB-9E67-C32AAE5588DFQ47801493-8917C0DE-E140-4D23-9AEA-95FBA1C4174BQ47962906-88E27891-5CB5-4BD1-9185-E8DEA6F6CD4D
P2860
Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Contribution of high plasma tr ...... ipoprotein cholesterol control
@ast
Contribution of high plasma tr ...... ipoprotein cholesterol control
@en
type
label
Contribution of high plasma tr ...... ipoprotein cholesterol control
@ast
Contribution of high plasma tr ...... ipoprotein cholesterol control
@en
prefLabel
Contribution of high plasma tr ...... ipoprotein cholesterol control
@ast
Contribution of high plasma tr ...... ipoprotein cholesterol control
@en
P2093
P2860
P921
P1476
Contribution of high plasma tr ...... ipoprotein cholesterol control
@en
P2093
Benjamin J Harshfield
Carolyn Kwiat
Frank M Sacks
Louise Bishop
Nancy Laranjo
Vincent J Carey
P2860
P304
P356
10.1016/J.AMJCARD.2010.05.002
P407
P577
2010-08-01T00:00:00Z